Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).
Locati LD, Perrone F, Losa M, Mela M, Casieri P, Orsenigo M, Cortelazzi B, Negri T, Tamborini E, Quattrone P, Bossi P, Rinaldi G, Bergamini C, Calderone RG, Liberatoscioli C, Licitra L. Locati LD, et al. Among authors: liberatoscioli c. Oral Oncol. 2009 Nov;45(11):986-90. doi: 10.1016/j.oraloncology.2009.05.635. Epub 2009 Jul 1. Oral Oncol. 2009. PMID: 19574086
Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study.
Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, Liberatoscioli C, Quattrone P, Calderone RG, Rinaldi G, Pilotti S, Licitra L. Locati LD, et al. Among authors: liberatoscioli c. Oral Oncol. 2009 Jul;45(7):574-8. doi: 10.1016/j.oraloncology.2008.07.010. Epub 2008 Sep 18. Oral Oncol. 2009. PMID: 18804410 Clinical Trial.
Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients.
Bossi P, Liberatoscioli C, Bergamini C, Locati LD, Fava S, Rinaldi G, Orlandi E, Olmi P, Tagliabue E, Ménard S, Licitra L. Bossi P, et al. Among authors: liberatoscioli c. Ann Oncol. 2007 Mar;18(3):601-2. doi: 10.1093/annonc/mdl409. Epub 2006 Oct 30. Ann Oncol. 2007. PMID: 17074970 Free article. No abstract available.
EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.
Lalami Y, Specenier PM, Awada A, Lacombe D, Liberatoscioli C, Fortpied C, El-Hariry I, Bogaerts J, Andry G, Langendijk JA, Vermorken JB. Lalami Y, et al. Among authors: liberatoscioli c. Radiother Oncol. 2012 Nov;105(2):238-40. doi: 10.1016/j.radonc.2012.08.006. Epub 2012 Sep 16. Radiother Oncol. 2012. PMID: 22989664 Clinical Trial.
Design and performance of clinical trials in head and neck cancer.
Awada A, Lacombe D, Liberatoscioli C. Awada A, et al. Among authors: liberatoscioli c. Curr Opin Oncol. 2010 May;22(3):184-5. doi: 10.1097/CCO.0b013e3283376aa8. Curr Opin Oncol. 2010. PMID: 20150810 Review. No abstract available.
Radiologists in Head and Neck Cancers Radiotherapy Peer Review.
Ramkumar S, Oguejiofor K, Liberatoscioli C, Boon IS. Ramkumar S, et al. Among authors: liberatoscioli c. Clin Oncol (R Coll Radiol). 2024 Dec 14;39:103734. doi: 10.1016/j.clon.2024.103734. Online ahead of print. Clin Oncol (R Coll Radiol). 2024. PMID: 39809130 No abstract available.